Iatrogenics
The WHO in 1969 described drug iatrogenics as “all the harmful, unintended and undesirable effects of a drug, occurring at dosages normally used in humans for prophylactic, diagnostic and therapeutic purposes, or for changes in physiological functions.” Drug-induced iatrogenesis is multifactorial and requires multidisciplinary and dedicated care.
The Public health Law of August 9, 2004 lists medicinal iatrogenics as a public health priority with the objectives of strengthening the quality of care and reducing iatrogenics linked to health products.
The creation of expert centers for the prevention and management of drug-induced iatrogenesis (CEPPIM) in healthcare establishments in the region is therefore an opportunity to respond to this priority.
MPI
Potentially inappropriate medications (PIMs) frequently comprise the chronic treatment of patients over 65 years of age.
The prescription of MPI in an elderly patient is one of the predictive factors of hospitalizations for iatrogenics and falls and therefore constitutes a public health problem. In terms of relevance of treatment, it is estimated in France that 6 to 10% of hospital admissions result from a problem of drug-induced iatrogenics.
